Postmarketing Surveillance Study for a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Republic of Korea
Phase of Trial: Phase IV
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Japanese encephalitis vaccine (Primary)
- Indications Japanese encephalitis
- Focus Adverse reactions
- Sponsors sanofi pasteur
- 27 Jul 2017 Status changed from active, no longer recruiting to recruiting.
- 28 Jun 2017 Planned End Date changed from 1 Dec 2019 to 29 Nov 2017.
- 28 Jun 2017 Planned primary completion date changed from 1 Sep 2019 to 29 Nov 2018.